These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31230714)

  • 1. Programmable RNA-Guided RNA Effector Proteins Built from Human Parts.
    Rauch S; He E; Srienc M; Zhou H; Zhang Z; Dickinson BC
    Cell; 2019 Jun; 178(1):122-134.e12. PubMed ID: 31230714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases.
    Kim D; Luk K; Wolfe SA; Kim JS
    Annu Rev Biochem; 2019 Jun; 88():191-220. PubMed ID: 30883196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR-Cas systems: ushering in the new genome editing era.
    Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
    Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR technologies and the search for the PAM-free nuclease.
    Collias D; Beisel CL
    Nat Commun; 2021 Jan; 12(1):555. PubMed ID: 33483498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas Derivatives as Novel Gene Modulating Tools: Possibilities and In Vivo Applications.
    Xu X; Hulshoff MS; Tan X; Zeisberg M; Zeisberg EM
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Performance Allosteric Conditional Guide RNAs for Mammalian Cell-Selective Regulation of CRISPR/Cas.
    Hochrein LM; Li H; Pierce NA
    ACS Synth Biol; 2021 May; 10(5):964-971. PubMed ID: 33930275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmable RNA targeting with the single-protein CRISPR effector Cas7-11.
    Özcan A; Krajeski R; Ioannidi E; Lee B; Gardner A; Makarova KS; Koonin EV; Abudayyeh OO; Gootenberg JS
    Nature; 2021 Sep; 597(7878):720-725. PubMed ID: 34489594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in stem cells and gene editing: Drug discovery and therapeutics.
    Bayarsaikhan D; Bayarsaikhan G; Lee B
    Prog Mol Biol Transl Sci; 2021; 181():231-269. PubMed ID: 34127195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases.
    Rasoulinejad SA; Maroufi F
    Mol Biotechnol; 2021 Sep; 63(9):768-779. PubMed ID: 34057656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28.
    Smargon AA; Cox DBT; Pyzocha NK; Zheng K; Slaymaker IM; Gootenberg JS; Abudayyeh OA; Essletzbichler P; Shmakov S; Makarova KS; Koonin EV; Zhang F
    Mol Cell; 2017 Feb; 65(4):618-630.e7. PubMed ID: 28065598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guide RNAs: A Glimpse at the Sequences that Drive CRISPR-Cas Systems.
    Briner AE; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Chromatin Organization and Epigenetics on CRISPR-Cas and TALEN Genome Editing.
    Jain S; Xun G; Zhao H
    ACS Synth Biol; 2024 Oct; 13(10):3056-3068. PubMed ID: 39315937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Prokaryotic CRISPR-Cas12a-Based Tool for Programmable Transcriptional Activation and Repression.
    Schilling C; Koffas MAG; Sieber V; Schmid J
    ACS Synth Biol; 2020 Dec; 9(12):3353-3363. PubMed ID: 33238093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors.
    Konermann S; Lotfy P; Brideau NJ; Oki J; Shokhirev MN; Hsu PD
    Cell; 2018 Apr; 173(3):665-676.e14. PubMed ID: 29551272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in CRISPR technologies for genome editing.
    Song M; Koo T
    Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein.
    Yan WX; Chong S; Zhang H; Makarova KS; Koonin EV; Cheng DR; Scott DA
    Mol Cell; 2018 Apr; 70(2):327-339.e5. PubMed ID: 29551514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications.
    Pyzocha NK; Chen S
    ACS Chem Biol; 2018 Feb; 13(2):347-356. PubMed ID: 29121460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad range plastid genome editing with monomeric TALE-linked cytosine and dual base editors.
    Wang X; Fang T; Lu J; Tripathi L; Qi Y
    Plant Biotechnol J; 2024 Sep; 22(9):2441-2443. PubMed ID: 38709858
    [No Abstract]   [Full Text] [Related]  

  • 19. CRISPR-Based Technologies: Impact of RNA-Targeting Systems.
    Terns MP
    Mol Cell; 2018 Nov; 72(3):404-412. PubMed ID: 30388409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Manipulation Using Fusion Guide RNAs for Cas9 and Cas12a.
    Shin HR; Kweon J; Kim Y
    Methods Mol Biol; 2021; 2162():185-193. PubMed ID: 32926383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.